CENPF Antibodies as Potential Cancer Markers

Mon, 09/17/2012 - 10:49

Centromere protein F (CENPF), also named mitosin, is a large human protein of 3113 amino acid residues. Its expression and localization are cell cycle-dependent. The protein levels are low in G1 phase but elevated from S to early M phase. CENPF is a nuclear matrix protein in interphase but is relocated to the kinetochore, the major site of microtubule attachment on chromosome, in M phase (1). Accumulating evidence suggests that CENPF is an important protein involved in chromosome alignment and kinetochore-microtubule interaction.

Western Blot: CENPF Antibody

Depletion of CENP-F results in chromosome misalignment and improper microtubule-kinetochore attachment. It interacts directly with many proteins including CENPE, NudE, ATF4, and Rb, thereby modulating cell fate (2). CENPF was found to be upregulated in nasopharyngeal carcinoma cell lines and tissues. Immunohistochemistry analysis using anti-CENPF antibodies revealed that CENPF expression was positively correlated with clinicopathological features and inversely correlated with overall survival (3). High expression levels of the CENPF as determined by antibodies against CENPF in several breast cancer tissues appeared to be responsible for the higher proliferative activity, in breast cancer, suggesting that CNPF levels in primary breast cancers may serve as a predictor of proliferation activity and aggressiveness of tumor cells (4). Taken together, these results suggest that CENPF could be a potential prognostic biomarker for clinical outcome and a promising indicator for selective therapeutic treatment for several cancers.

  1. PMID: 7904902
  2. PMID: 645671
  3. PMID: 20828406
  4. PMID: 9102762

Novus Biologicals offers CENPF reagents for your research needs including:


Blog Topics